Qrons IncOTCQB:QRON
- LAST PRICE0.5030
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.5030
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Jan 17, 2023
Qrons Announces Engagement of Israeli Intellectual Property Law Firm IPK to Develop Roadmap for Its New Product Line, from 9:01AM ET on Tuesday Jan 17, 2023 by Accesswire
9:01AM ET on Tuesday Jan 17, 2023 by Accesswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Qrons Inc | 6.7M | -7.2x | --- |
GlobeStar Therapeutics Corp | 6.7M | -0.9x | --- |
Windtree Therapeutics Inc | 6.5M | -0.1x | --- |
X T L Biopharmaceuticals Ltd | 7.0M | -2.3x | --- |
Avenue Therapeutics Inc | 7.0M | -0.4x | --- |
Revelation Biosciences Inc | 6.1M | -15.7x | --- |
Company Information
Qrons Inc. is a biotechnology company. The Company is focused on developing biotech products, treatments and technologies to combat neuronal diseases. It seeks to engage in arrangements with companies and institutions that are developing technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in neuronal diseases. The Company has developed two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries. Both QS100TM and QS200TM integrate, anti-brain inflammation synthetic hydrogel and modified mesenchymal stem cells (MSCs) and smart synthetic material. Its QS100TM is an injury-specific, three-dimensional (3D) printable, implantable MSCs-synthetic hydrogel to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries referred to concussions.
Contact Information
- Headquarters
- 28-10 JACKSON AVENUE, #26NLONG ISLAND CITY, NY, United States 11101
- Phone
- 212-945-2080
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-0.07 |
Book Value | $-0.08 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
